Acute Respiratory Distress Syndrome (ARDS)
Pulmonary hyperinflammation is a major contributor to disease progression and poor outcomes
Evidence from COVID- 19 patients has identified hyperinflammation as a major contributor to disease progression and outcomes, and reduction of hyperinflammatory mediators such as TNF via TAK1 inhibition may provide a novel therapeutic axis for the treatment of severe COVID-19 patients.
How our technology can be applied
Targeting pulmonary hyperinflammation that underlies severe COVID-19 infections
Our preclinical work has identified TGFβ-activated kinase 1 (TAK1) as a key element within the signaling pathway which drives COVID-19 induced cytokine storm leading to ARDS. TAK1 inhibition with our first-in-class orally bioavailable TAK1 inhibitor EYD-001 has been shown to potently reduce TNF signaling at target sites of disease, as well as inhibit the trafficking of nucleated immune cells into the lungs, in vivo.
Benefits of Our Application
Orally bioavailable small
Selective targeting of
Additional information and resources
EydisBio is a small biotech located in Durham, North Carolina. Originally created as a spinout of Duke University, EydisBio has gone on to become a leader for the development of selective and potent small molecule inhibitors of disease relevant kinases.